Maria Kjellsson
Professor at Department of Pharmacy; Pharmacometrics
- Telephone:
- +46 18 471 40 09
- E-mail:
- maria.kjellsson@uu.se
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postal address:
- Box 580
751 23 UPPSALA
Download contact information for Maria Kjellsson at Department of Pharmacy; Pharmacometrics
Professor at Department of Pharmacy; Pharmacometrics
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postal address:
- Box 580
751 23 UPPSALA
Download contact information for Maria Kjellsson at Department of Pharmacy; Pharmacometrics
- CV:
- Download CV
- ORCID:
- 0000-0003-3531-9452
Short presentation
Maria Kjellsson is a professor of Pharmacokinetics and an associate professor (Sv. docent) in Pharmacometrics. She is part of the large and successful research unit Pharmacometrics, which is lead by Mats Karlsson.
Biography
Title: Professor in Pharmacokinetics
Position: Professor at the Department of Pharmacy
Research area: Pharmacometric diabetes modelling, Pharmacometric methodology
Research interest:
My research interest is diabetes; mainly type 2, also known as adult on-set diabetes. I co-lead the pharmacometric diabetes group together with Mats Karlsson and we use mixed-effects models to investigate, describe and quantify various time-varying aspects of diabetes, such as disease progression and treatment effects.
Diabetes affects around 285 million people worldwide and due to ageing population, obesity and sedentary life-style, the number of diabetics is likely to increase with 54% by 2030. Apart from the acute feelings of illness elevated glucose levels cause, diabetes also causes long-term complications, including coronary heart disease, blindness and kidney-disease. Diabetes treatment includes life-style changes, such as sugar-reduced diet and exercise but also pharmacological treatment.
What do we do:
The models we are developing span from describing pre-clinical provocations experiments, clinical provocations and HbA1c studies all the way to models describing cardio-vascular disease (CVD) and kidney disease using registry data.
The intended use of the models also varies greatly. Some models would be used by discovery teams in drug industry to translate animal experiments to human studies and pick the best drug dose for humans. Some models are being used in drug development to help optimize clinical study design, perform clinical trial simulations and quantify drug effects. And yet some would be used to predict the long-term gain of a treatment on HbA1c or even the risk of CVD in relation to diabetes.
We are, apart from investigating effects of drug, also investigating the relationship between weight change and insulin sensitivity. Decreased insulin sensitivity is a pre-state of diabetes and understanding the process leading up to diabetes from a whole-body modelling perspective, taking into account genetic information, is also one of our newer research projects.

Publications
Recent publications
Part of CPT, p. 606-615, 2025
- DOI for Modeling of Disease Progression of Type 2 Diabetes Using Real-World Data: Quantifying Competing Risks of Morbidity and Mortality
- Download full text (pdf) of Modeling of Disease Progression of Type 2 Diabetes Using Real-World Data: Quantifying Competing Risks of Morbidity and Mortality
Part of British Journal of Clinical Pharmacology, 2024
- DOI for Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney‐transplanted patients
- Download full text (pdf) of Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney‐transplanted patients
Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea
Part of CPT, p. 880-890, 2024
- DOI for Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea
- Download full text (pdf) of Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea
Evaluation of covariate effects in item response theory models
Part of CPT, p. 812-822, 2024
- DOI for Evaluation of covariate effects in item response theory models
- Download full text (pdf) of Evaluation of covariate effects in item response theory models
Part of CPT, p. 1529-1540, 2023
- DOI for Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP-1
- Download full text (pdf) of Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP-1
All publications
Articles in journal
Part of CPT, p. 606-615, 2025
- DOI for Modeling of Disease Progression of Type 2 Diabetes Using Real-World Data: Quantifying Competing Risks of Morbidity and Mortality
- Download full text (pdf) of Modeling of Disease Progression of Type 2 Diabetes Using Real-World Data: Quantifying Competing Risks of Morbidity and Mortality
Part of British Journal of Clinical Pharmacology, 2024
- DOI for Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney‐transplanted patients
- Download full text (pdf) of Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney‐transplanted patients
Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea
Part of CPT, p. 880-890, 2024
- DOI for Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea
- Download full text (pdf) of Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea
Evaluation of covariate effects in item response theory models
Part of CPT, p. 812-822, 2024
- DOI for Evaluation of covariate effects in item response theory models
- Download full text (pdf) of Evaluation of covariate effects in item response theory models
Part of CPT, p. 1529-1540, 2023
- DOI for Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP-1
- Download full text (pdf) of Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP-1
Optimal dosing of gliclazide-A model-based approach
Part of Basic & Clinical Pharmacology & Toxicology, p. 59-72, 2023
- DOI for Optimal dosing of gliclazide-A model-based approach
- Download full text (pdf) of Optimal dosing of gliclazide-A model-based approach
Part of Endocrine Connections, 2023
- DOI for Altered glucose-dependent secretion of glucagon and ACTH is associated with insulin resistance, assessed by population analysis
- Download full text (pdf) of Altered glucose-dependent secretion of glucagon and ACTH is associated with insulin resistance, assessed by population analysis
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 21-31, 2023
Part of Clinical Pharmacology and Therapeutics, p. 112-124, 2022
- DOI for Impact of Obesity on Postprandial Triglyceride Contribution to Glucose Homeostasis, Assessed with a Semimechanistic Model
- Download full text (pdf) of Impact of Obesity on Postprandial Triglyceride Contribution to Glucose Homeostasis, Assessed with a Semimechanistic Model
Part of CPT, p. 1443-1457, 2022
- DOI for Optimization of trial duration to predict long-term HbA1c change with therapy: A pharmacometrics simulation-based evaluation
- Download full text (pdf) of Optimization of trial duration to predict long-term HbA1c change with therapy: A pharmacometrics simulation-based evaluation
Optimal Designs for Model-Based Assessment of Insulin Sensitivity and Glucose Effectiveness.
Part of Journal of clinical pharmacology, p. 116-124, 2021
- DOI for Optimal Designs for Model-Based Assessment of Insulin Sensitivity and Glucose Effectiveness.
- Download full text (pdf) of Optimal Designs for Model-Based Assessment of Insulin Sensitivity and Glucose Effectiveness.
Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data
Part of AAPS Journal, 2021
- DOI for Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data
- Download full text (pdf) of Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data
Part of Diabetes, obesity and metabolism, p. 1001-1010, 2021
- DOI for Postprandial triglyceride reduction following acute treatment of a selective 5-hydroxytryptamine-2c agonist and characterization using a semi-physiological model
- Download full text (pdf) of Postprandial triglyceride reduction following acute treatment of a selective 5-hydroxytryptamine-2c agonist and characterization using a semi-physiological model
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 815-823, 2021
- DOI for Linking categorical models for prediction of pleasantness score using individual predictions of sweetness and creaminess: An advancement of categorical modeling
- Download full text (pdf) of Linking categorical models for prediction of pleasantness score using individual predictions of sweetness and creaminess: An advancement of categorical modeling
An Item Response Theory-Informed Strategy to Model Total Score Data from Composite Scales
Part of AAPS Journal, 2021
- DOI for An Item Response Theory-Informed Strategy to Model Total Score Data from Composite Scales
- Download full text (pdf) of An Item Response Theory-Informed Strategy to Model Total Score Data from Composite Scales
Part of Clinical Pharmacology and Therapeutics, p. 416-423, 2021
Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response
Part of Pharmaceutical research, 2020
- DOI for Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response
- Download full text (pdf) of Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response
Sweet/Fat Preference Taste in Subjects who are Lean, Obese and Very Obese
Part of Pharmaceutical research, 2020
- DOI for Sweet/Fat Preference Taste in Subjects who are Lean, Obese and Very Obese
- Download full text (pdf) of Sweet/Fat Preference Taste in Subjects who are Lean, Obese and Very Obese
Part of Clinical Pharmacology and Therapeutics, p. 238-245, 2020
Variability Attribution for Automated Model Building
Part of AAPS Journal, 2019
- DOI for Variability Attribution for Automated Model Building
- Download full text (pdf) of Variability Attribution for Automated Model Building
Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment
Part of AAPS Journal, 2019
- DOI for Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment
- Download full text (pdf) of Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment
A Bounded Integer Model for Rating and Composite Scale Data
Part of AAPS Journal, 2019
- DOI for A Bounded Integer Model for Rating and Composite Scale Data
- Download full text (pdf) of A Bounded Integer Model for Rating and Composite Scale Data
The Integrated Glucose Insulin Minimal Model: An improved version
Part of European Journal of Pharmaceutical Sciences, p. 7-19, 2019
Translation between two models; Application with integrated glucose homeostasis models
Part of Pharmaceutical research, 2019
- DOI for Translation between two models; Application with integrated glucose homeostasis models
- Download full text (pdf) of Translation between two models; Application with integrated glucose homeostasis models
Part of Basic & Clinical Pharmacology & Toxicology, p. 105-114, 2019
Model-Based Residual Post-Processing for Residual Model Identification
Part of AAPS Journal, 2018
- DOI for Model-Based Residual Post-Processing for Residual Model Identification
- Download full text (pdf) of Model-Based Residual Post-Processing for Residual Model Identification
Part of CPT, p. 331-341, 2018
Part of Diabetes, obesity and metabolism, p. 660-666, 2018
Part of CPT, p. 432-441, 2018
- DOI for Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests
- Download full text (pdf) of Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests
Part of Clinical Pharmacokinetics, p. 591-599, 2018
- DOI for Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
- Download full text (pdf) of Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
Part of Journal of Pharmacokinetics and Pharmacodynamics, 2018
Part of CPT, p. 686-694, 2017
Model-Based Interspecies Scaling of Glucose Homeostasis
Part of CPT, p. 778-786, 2017
- DOI for Model-Based Interspecies Scaling of Glucose Homeostasis
- Download full text (pdf) of Model-Based Interspecies Scaling of Glucose Homeostasis
Part of Journal of Pharmacokinetics and Pharmacodynamics, 2017
Comparison of diagnostics using model-based post-processing for fast automated model building
Part of Journal of Pharmacokinetics and Pharmacodynamics, 2017
Impact of demographics and disease progression on the relationship between glucose and HbA1c
Part of European Journal of Pharmaceutical Sciences, p. 417-423, 2017
Modeling the Disease Progression from Healthy to Overt Diabetes in ZDSD Rats
Part of AAPS Journal, p. 1203-1212, 2016
Part of CPT, p. 388-9, 2016
Weight-HbA1c-Insulin-Glucose Model for Describing Disease Progression of Type 2 Diabetes
Part of CPT, p. 11-19, 2016
- DOI for Weight-HbA1c-Insulin-Glucose Model for Describing Disease Progression of Type 2 Diabetes
- Download full text (pdf) of Weight-HbA1c-Insulin-Glucose Model for Describing Disease Progression of Type 2 Diabetes
Part of Journal of clinical pharmacology, p. 340-348, 2016
Part of Journal of Pharmacokinetics and Pharmacodynamics, 2016
Part of British Journal of Clinical Pharmacology, p. 1613-1624, 2016
Mechanistic modeling of hepatic pitavastatin disposition: a proteomics-informed bottom-up approach
Part of Drug metabolism reviews (Softcover ed.), p. 56-57, 2016
Part of Drug Metabolism And Disposition, p. 505-516, 2016
Nonlinear mixed-effects modelling for single cell estimation: when, why, and how to use it
Part of BMC Systems Biology, 2015
- DOI for Nonlinear mixed-effects modelling for single cell estimation: when, why, and how to use it
- Download full text (pdf) of Nonlinear mixed-effects modelling for single cell estimation: when, why, and how to use it
Part of CPT, p. 1-9, 2015
- DOI for The Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model
- Download full text (pdf) of The Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model
Interspecies scaling of dynamic glucose and insulin using a mathematical model approach
Part of Diabetologia, 2015
Part of Diabetologia, 2015
Part of CPT, 2014
Part of Journal of clinical pharmacology, p. 809-817, 2014
Part of CPT, 2013
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 1-10, 2013
Part of Journal of clinical pharmacology, p. 589-600, 2013
Part of Journal of Pharmacokinetics and Pharmacodynamics, 2013
Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions
Part of Antimicrobial Agents and Chemotherapy, p. 446-457, 2012
Abscess penetration of cefpirome: concentrations and simulated pharmacokinetic profiles in pus
Part of European Journal of Clinical Pharmacology, p. 1419-1423, 2012
Good penetration of moxifloxacin into human abscesses
Part of Pharmacology, p. 146-150, 2012
Modeling sleep data for a new drug in development using Markov mixed-effects models
Part of Pharmaceutical research, p. 2610-2627, 2011
Evaluation of the Nonparametric Estimation Method in NONMEM VI
Part of European Journal of Pharmaceutical Sciences, p. 27-35, 2009
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 81-99, 2009
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 483-501, 2008
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 299-320, 2004
The effects of dose staggering on metabolic drug-drug interactions
Part of European Journal of Pharmaceutical Sciences, p. 223-232, 2003
Articles, review/survey
Comprehensive doctoral thesis
Conference papers
Part of 2020 American Control Conference (ACC), p. 1323-1328, 2020